VRCA Q2 2023 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$56M

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$182,000-15.0% YoY

Gross Profit

$46,00025.3% margin

Operating Income

-$12M-6382.4% margin

Net Income

-$11M-6038.5% margin

EPS (Diluted)

$-2.39

QoQ Revenue Growth

+391.9%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$62M

Total Liabilities

$7M

Stockholders' Equity

$55M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$182,000	$214,000	-15.0%
Gross Profit	$46,000	-$5,000	+1020.0%
Operating Income	-$12M	-$9M	-27.4%
Net Income	-$11M	-$10M	-8.1%